Table 1.
Parameter | Symbol | Formula | Value | Source |
---|---|---|---|---|
Transmission probability | β | R0/ND | N/A | |
Scenario 1a | 2.74 × 10−5 contacts per day | |||
Scenario 2b | 6.12 ×10−5 contacts per day | |||
Basic reproduction number | R0 | R/s | N/A | |
Scenario 1 | 7.14 | |||
Scenario 2 | 16.0 | |||
Reproduction number of cases prior to initiation of control measures | R | N/A | 4.22 | Likelihood-based estimation procedure (8, 10) |
Proportion of the population that is susceptible at outset | s | VCc (1 − VEd,e) + sUf,g (1 − VC) | N/A | |
Scenario 1 | 0.59 | |||
Scenario 2 | 0.26 | |||
Population size | N | S + E + I + R | 32,630 | Young Center for Anabaptist and Pietist Studies, Elizabethtown College (14) |
Average preinfectious or latency period | N/A | N/A | 10 days | CDC measles surveillance manual (16) and ACIP recommendations (12) |
Average duration of infectiousness | D | N/A | 9 days | CDC measles surveillance manual (16) and ACIP recommendations (12) |
Infectiousness rate (proportion of exposed persons who become infectious) | σ | 1/average preinfectious or latency period | 0.1 persons per day | N/A |
Recovery rate (proportion of infectious persons who become immune) | γ | 1/average duration of infectiousness | 0.1 persons per day | N/A |
Abbreviations: ACIP, Advisory Committee on Immunization Practices; CDC, Centers for Disease Control and Prevention; MMR, measles-mumps-rubella; N/A, not applicable.
a Assuming ≥1-dose MMR vaccine coverage of 14% to calculate s (lower bound)—from a coverage assessment in a subset of affected Amish families (5).
b Assuming ≥1-dose MMR vaccine coverage of 68% to calculate s (upper bound)—from the literature (13).
cVC represents vaccine coverage (≥1 dose of MMR vaccine).
dVE represents vaccine effectiveness (median effectiveness of 1 dose of MMR vaccine).
eVE = 93% (12).
fsU represents the proportion of unvaccinated persons who are susceptible.
g unvax.S = 67.5%—from a household transmission study conducted during the outbreak.